NCL-195
Neuroblastoma and other solid tumors
Key Facts
About Aptorum Group
Aptorum Group is a clinical-stage biotech with a mission to facilitate life science innovations that tackle unmet medical needs, particularly in oncology and infectious diseases. Its strategy combines internal discovery platforms, including computational and AI-enhanced methods for drug repurposing and novel target identification, with the acquisition of external clinical-stage assets to build its portfolio. The company's primary achievements include advancing its lead candidates, ALS-4 for MRSA and NCL-195 for neuroblastoma, through preclinical development while maintaining a lean operational structure. Its outlook hinges on successfully transitioning these assets into clinical trials to generate human proof-of-concept data.
View full company profile